← All diseases
Liver, kidneys and digestion
Liver cirrhosis
Would you like to receive a message when there is new research about Liver cirrhosis? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence above each publication explains what was studied — and you'll be notified as soon as new research on Liver cirrhosis is available. View what Premium costs.
Publications and studies (3127)
- MASH and the race for liver antifibrotics. (2026/01/23) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Gut microbiota, liver disease, and perioperative anesthesia: interactions, risks, and therapeutic opportunities. (2026/01/22) ♡
- Hyperoside attenuates NASH-associated liver fibrosis by modulating Flot2/TLR4 signaling and pyroptosis. (2026/01/15) ♡
- Determinants of Skeletal Muscle Preservation in Patients with Chronic Liver Disease. (2026/01/15) ♡
- Knowledge, attitudes, and practices of liver cirrhosis patients regarding dietary nutrition. (2026/01/06) ♡
- Diagnostic value of non-invasive indices for assessing liver fibrosis in Chinese children with metabolic dysfunction-associated steatotic liver disease. (2026/01/06) ♡
- Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort. (2026/01/06) ♡
- Nitrogen recycling by the gut microbiome in sarcopenia. (2026/01/05) ♡
- Low muscle density and five times sit-to-stand test predict poor outcome in liver transplant candidates. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Nutrition in Hepatocellular Carcinoma: Pathophysiological Insights, Impact, and Implications for Clinical Practice. (2026/01/01) ♡
- Diverse impacts of cadmium exposure on adolescent liver health: Suppression of steatosis and promotion of fibrosis. (2026/01/01) ♡
- Inhibiting VEGFC - mediated hepatocyte - macrophage regulatory axis contributes to protective effects of naringin against high - fat diet - induced hepatic fibrosis. (2026/01/01) ♡
- Effective Components and Molecular Mechanism of Biejiaruangan Capsule Against Liver Fibrosis: High-resolution Mass Spectrometry, Network Pharmacological Analysis and Experimental Verification. (2026/01/01) ♡
- Mechanisms Underlying the Attenuating Effects of Bugantang on Liver Fibrosis Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation. (2026/01/01) ♡
- Compound Gardenia Radix Granule mitigates liver fibrosis in CCl(4)-induced mice by repressing SphK1-S1PR2 axis-mediated p-ERK signaling. (2026/01/01) ♡
- Study on the anti-liver cirrhosis of Fuzheng Huayu tablet : Targeting macrophage PPARα axis-fatty acid metabolic. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Electroencephalography in hepatic encephalopathy: diagnostic and prognostic applications across the disease spectrum. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Dual Role of Saikosaponins in Liver Disease Treatment: A Comprehensive Review of Pharmacological Activities and Toxicological Characteristics. (2026/01/01) ♡
- Precision switching from entecavir to tenofovir alafenamide in chronic hepatitis B: matching the patient phenotype to efficacy, safety, and value: a narrative review. (2026/01/01) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis (2026-08-11) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis (2026-08-11) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Predicting Response and Exposure Changes in Cirrhosis for Effectiveness (2026-08-11) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis (2026-08-10) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis: an RCT (2026-08-10) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease (2026-08-10) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis (2026-08-10) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis (2026-08-10) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Isocaloric Navy-Bean Substitution in Adults With MASLD (2026-08-10) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. TruGraf Liver Gene Expression Serial Test (2026-08-07) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy (2026-08-07) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response (2026-08-06) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Bilirubin Increases the Risk of Nosocomial Infection in Cirrhotic Patients (2026-08-06) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (2026-08-06) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention (2026-08-06) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (2026-08-05) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) (2026-08-05) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis (2026-08-05) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Adverse Outcomes and Mortality in Liver Transplant (2026-08-05) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (2026-08-05) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) (2026-08-05) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Integrating Care for Patients With Alcohol Liver Disease and Alcohol Use Disorders (2026-08-04) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (2026-08-04) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (2026-08-04) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients With Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement (2026-08-04) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease Progression (2026-08-04) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (2026-08-03) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy (2026-08-03) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe (2026-08-03) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (2026-08-03) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (2026-08-03) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.